

PSAP 2021 Book 3 (*Chronic Conditions and Public Health*)

Release date: September 15, 2021

BCPS test deadline: 11:59 p.m. (Central) on March 15, 2022.

ACPE test deadline: 11:59 p.m. (Central) on September 15, 2024.



Continuing Pharmacy Education (CPE) Credit: The American College of Clinical

Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of CPE.

PSAP Target Audience: The target audience for PSAP 2021 Book 3 (*Chronic Conditions and Public Health*) is pharmacotherapy specialists and advanced level clinical pharmacists encountering patients with chronic diseases and/or a need for public health–related services.

Module I (4.5 CPE): 0217-0000-21-040-H01-P

Chapter: Drug Interactions: Scientific and Clinical Principles

Learning Objectives

1. Assess patients on the basis of the incidence of drug interactions and their potential outcomes.
2. Distinguish the mechanisms behind various drug interactions and their impact on patients.
3. Develop strategies for identifying and mitigating potential drug interactions.
4. Evaluate the strengths and weaknesses of available drug interaction resources.

Chapter: Monitoring of Adverse Drug Reactions and REMS

Learning Objectives

1. Using validated tools, assess patients for the risk of an adverse drug reaction (ADR).
2. Evaluate an ADR program to determine whether quality metrics are being met with appropriate feedback to stakeholders.
3. Evaluate a plan to monitor a Risk Evaluation and Mitigation Strategies (REMS) program to ensure compliance with regulations and training of personnel.
4. Evaluate the elements for creating a multidisciplinary approach to a REMS program to enhance optimal patient outcomes.
5. Develop a plan to ensure patient safety that incorporates ADR reporting and REMS reporting and compliance.

Module II (5.5 CPE): 0217-0000-21-041-H01-P

Chapter: Patient Wellness, Health Screening, and Preventive Medicine

Learning Objectives

1. Evaluate opportunities to promote and implement wellness prevention interventions and/or programs.

2. Distinguish among the various wellness initiatives that may affect a patient's care and pharmacotherapeutic care plan.
3. Develop a wellness plan that incorporates a patient's risk factors and comorbidities.
4. Justify when patients should receive preventive screenings, and determine a timeline for when they should be performed.
5. Evaluate the available technological support systems designed to aid the clinician and patient in wellness and prevention decisions.

Chapter: Pregnancy Wellness and Antenatal Care

Learning Objectives

1. Design a nutritional support plan for a pregnant patient in the first trimester of pregnancy.
2. Design a complete treatment plan for a pregnant patient with diabetes, including monitoring recommendations, nonpharmacologic therapy, pharmacologic therapy, and pertinent patient education.
3. Design a complete treatment plan for a pregnant patient with chronic hypertension, including monitoring recommendations, nonpharmacologic therapy, pharmacologic therapy, and pertinent patient education.
4. Design a complete treatment plan for a pregnant patient with a thyroid disorder, including monitoring recommendations, pharmacologic therapy, and pertinent patient education.
5. Design a complete treatment plan for a pregnant patient with a history of depression, anxiety, and/or bipolar disorder, including monitoring recommendations, pharmacologic therapy, and pertinent patient education.
6. Develop a preconception plan for a patient with diabetes, chronic hypertension, a thyroid disorder, and/or a mental health disorder during pregnancy.

Chapter: Routine Adult Immunizations and COVID-19 Vaccines

Learning Objectives

1. Assess patient risk factors for common vaccine-preventable diseases.
2. Distinguish the characteristics of various available vaccines for influenza, pneumococcal disease, meningococcal disease, herpes zoster, tetanus diphtheria pertussis, hepatitis A, hepatitis B, and coronavirus disease 2019.
3. Design a patient-specific immunization regimen on the basis of age, risk factors, and comorbid conditions.
4. Apply strategies for effectively addressing pseudoscience and vaccine hesitancy.

Module III (4.5 CPE): 0217-0000-21-042-H01-P

Interactive Case: Psoriasis

Learning Objectives

1. Apply data from contemporary studies of epidemiology and pathophysiology to the assessment and treatment of patients with psoriasis.
2. Evaluate the severity of a patient's psoriasis in order to justify a general treatment approach.
3. Develop an evidence-based treatment regimen to manage the clinical manifestations of a patient's psoriasis.

4. Develop a plan for screening and managing psoriasis-related comorbidities and adverse effects of therapy according to current guidelines.
5. Design a treatment plan to treat special populations of patients with psoriasis.

Interactive Case: Combination Therapies in BPH

Learning Objectives

1. Evaluate combination pharmacologic agents for the treatment of benign prostatic hyperplasia (BPH) or lower urinary tract symptoms (LUTS), including adverse effects and monitoring.
2. Design an appropriate treatment approach for a patient with BPH/LUTS, including the role of combination therapy.